Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028819 | 0.89 | KIT (0.39) | KITFYNMAPTMAPK1THRB | |
| SCHEMBL6029906 | 0.89 | MCHR1 (0.40) | NPC1RAB9AMAPTKMT2ALMNA | |
| SCHEMBL6029743 | 0.82 | KMT2A (0.41) | NPC1POLBMAPTMAPK1KMT2A | |
| SCHEMBL6029207 | 0.81 | MCHR1 (0.38) | POLBMAPTKMT2ATSHRALDH1A1 | |
| SCHEMBL6029444 | 0.80 | L3MBTL1 (0.43) | POLBMAPTKMT2ATSHRALDH1A1 | |
| SCHEMBL6029146 | 0.78 | FYN (0.42) | KITFYNNPC1RAB9APOLB | |
| SCHEMBL6029113 | 0.76 | KMT2A (0.39) | NPC1RAB9APOLBMAPTKMT2A | |
| SCHEMBL6029398 | 0.76 | STK17B (0.36) | MAPK1HPGDPDE5ALMNANPSR1 | |
| SCHEMBL6029331 | 0.75 | LMNA (0.40) | RAB9APOLBMAPTTHRBKMT2A | |
| SCHEMBL6169605 | 0.75 | LMNA (0.38) | RAB9APOLBMAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984643-B2 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1521582-A1 | 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2004004731-A1 | 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | KIT 537/4885FYN 2872/4885NPC1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.